A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.
Latest Information Update: 18 Jul 2024
At a glance
- Drugs SG 1906 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Acronyms CSG-1906-101
- Sponsors Hangzhou Sumgen Biotech
Most Recent Events
- 16 May 2023 New trial record